Which agent: exercise if possible (AHA 2026). Possible dynamic narrowing (AAOCA with an inter-arterial or intramural course, myocardial bridge): dobutamine, not a vasodilator (AHA 2026; Fares 2019; ASNC 2026 p45, adult). Fixed obstruction, fistula: a vasodilator is an option.
Contraindications first: shared section
| Dose | ||
|---|---|---|
| Pediatric | 140 mcg/kg/min (0.14 mg/kg/min), 3 min before contrast. Adequacy and safety not thoroughly established in children. Fares 2019 proposes the same start, without a duration; the caveat and the 3 min are SCMR CHD 2013 (AHA 2026 Table 2 also gives 3 min). Youngest series: Buechel 2009, 56 examinations in 47 patients, 1 month to 18 y, 2.6 to 82 kg, 18 under general anesthesia, no significant complications; one study was non-diagnostic for body size at 2.7 kg. Scannell 2021 used the same dose in 14 patients. | SCMR CHD 2013 Fares 2019 |
| Proposed | Up to 210 mcg/kg/min. No pediatric cohort read escalated. Fares 2019: if after 2 to 3 min the heart rate has not risen 10 bpm and/or BP has not dropped by more than 10 mmHg, “depending on institutional and local norms”. SCMR 2025: if the stress response is inadequate. The citation beside this sentence (Brink 2015, abstract read) compares adverse effects in outpatients and does not address escalation; the wording matches the adult protocol in SCMR 2020. Buechel 2009, Scannell 2021 and SCMR CHD 2013 stay at 140. ASNC 2026, adult, prints no dose above 140. | Fares 2019 |
| Give, watch, stop | ||
| Pediatric | Two IV lines. Continuous ECG, BP every 2 min. BP cuff off the adenosine arm. SCMR 2025: one vein in each arm where possible; do not inflate the cuff during contrast; contrast at least 3 mL/s, or 2 mL/s in younger children. SCMR CHD 2013: in children a minimum of 3 ml/s with a 10 ml flush; consent covers dyspnea, flushing, headache, light-headedness, blurred vision, nausea, bronchospasm, heart block and hypotension; resuscitation equipment and qualified staff available. The BP interval is Buechel 2009. ASNC 2026, adult: BP every minute during the infusion, then every 2 min for at least 5 min. FDA label: ask about seizure history. | SCMR CHD 2013 |
| Pediatric | Stop for persistent or symptomatic heart block, significant hypotension or severe respiratory difficulty. | SCMR CHD 2013 |
| Reverse | ||
| Pediatric | Stop the infusion: half-life <10 s, Adult. No pediatric reversal dose in any document read. | ASNC 2026 Fares 2019 SCMR CHD 2013 |
| Adult | Not for a seizure (caffeine: sources disagree). Rescue, rarely needed: aminophylline 50–125 mg over 30 s, to 250 mg at most. When to reverse, Adult. Aminophylline over 30 s, may repeat, to 250 mg: ASNC 2026 p32. 50 to 125 mg by slow injection: Abidov 2018. History of seizures: aminophylline with caution (ASNC 2026 p51). The FDA label prints a theophylline dose, and ASNC 2026 p32 theophylline and caffeine doses; they are not shown here because those product labels were not read, and no document read gives a pediatric dose. Seizure: first line in adults is IV lorazepam (Abidov 2018, ASNC 2026); the FDA label advises against methylxanthines; ASNC 2026 prefers IV caffeine for reversal, so the sources disagree. | ASNC 2026 FDA label Abidov 2018 |
| Dose | ||
|---|---|---|
| Not child-specific | 140, up to 210 mcg/kg/min. | SCMR 2025 |
| Adult | 140, 170, then 210 mcg/kg/min, 7 min at most. Karamitsos 2010, 98 adults: 140 for at least 3 min, 170 for 2 min, 210 for 2 min, if heart rate rose <10 bpm or systolic BP fell <10 mmHg with minimal or no reported side effects; 18 of 98 escalated; more chest pain at the high dose (61% vs 29%). SCMR 2020: 140 for 2 to 4 min, consider up to 210 after 2 to 3 min. | Karamitsos 2010 SCMR 2020 |
| Adult | 140 mcg/kg/min for 6 min, or 4 min as an alternative. Higher risk (borderline hypotension, controlled asthma): start at 70–110 mcg/kg/min for 1 min, then 140. No dose above 140 printed. | ASNC 2026 |
Contraindications first: shared section
| Dose, single IV bolus | ||
|---|---|---|
| Pediatric | 6–8 mcg/kg, up to 400 mcg: most common. | SCMR 2025 |
| Pediatric | 8 mcg/kg if <40 kg; 400 mcg if ≥40 kg. Wilkinson 2019: 46 examinations in 36 patients under 40 kg; median 9.0 y (2 months to 13.9 y), median 27.6 kg (3.8 to 39.3 kg). Chosen below the adult maximum tolerated doses of 10 mcg/kg standing and 20 supine, for hemodynamic lability and sedation. No major adverse events. Noel 2018: the same split, a slight decrease from 10 mcg/kg; 36 patients after arterial switch, 15.1 ± 4.5 y (0.2 to 22 y), 3.8 to 93 kg, a small number under 40 kg, no serious adverse events. Noel 2017: 400 mcg; 31 patients, 12 to 22 y, 40 to 93 kg, all awake. Overlap, as the papers state it: 2 of Wilkinson 2019’s examinations were in Noel 2018, and 11 of Noel 2018’s patients were in Noel 2017. All from one center. | Wilkinson 2019 Noel 2018 |
| Proposed | 10 mcg/kg if <40 kg; 0.4 mg (400 mcg) if >40 kg. Top of the range: 1 patient of 38 in Patel 2022. The authors’ institutional protocol; no citation beside the 10 mcg/kg. In Patel 2022 that is 1 of 13 weight-based doses. Noel 2017 set its 40 kg limit as 40 kg × 10 mcg/kg = 400 mcg, half the adult supine maximum tolerated dose, and gave no one under 40 kg. Noel 2018 gave 8 mcg/kg under 40 kg. Patel 2022: earlier pediatric work used 8 to 10 mcg/kg. Exactly 40 kg is not addressed. | Fares 2019 |
| Pediatric | 6–10 mcg/kg, maximum 400 mcg. Of 38 patients, 12 received 6 mcg/kg, 1 received 10 mcg/kg and 25 received 400 mcg. Older cohort: median 15 y (IQR 12 to 17), median 61 kg (IQR 51 to 75); no general anesthesia. No major adverse events; 15 (39%) had transient minor side effects. | Patel 2022 |
| Adult | Fixed adult dose: not under 40 kg (our note). ASNC 2026 Table 10 prints 0.4 mg down to 25 kg and 50 lb: 16 to 18 mcg/kg, about twice the 8 mcg/kg above (our arithmetic). ASNC 2026 p4 says it focuses on adults; p20 says no adjustment for body size; the caption of Table 10 cites the 2016 guideline. 400 mcg at 25 kg is 16 mcg/kg; at 50 lb (22.7 kg), 17.6 mcg/kg. FDA label section 10: in healthy volunteers, flushing, dizziness and raised heart rate were intolerable above 0.02 mg/kg (20 mcg/kg). | ASNC 2026 FDA label |
| Give, watch | ||
| Pediatric | One IV line. BP every 3 min; monitor 1 hour after the study. Stress perfusion at 60 s (Wilkinson 2019) or 60 to 90 s (Patel 2022); adult, contrast about 45 to 60 s after the injection (SCMR 2020). Rest perfusion: once the heart rate approaches baseline (Fares 2019, proposed); 20 min (Wilkinson 2019). Patel 2022 schedule: heart rate and BP every minute for 5 min, every 5 min for 20 min, then every 10 to 15 min until an hour after the dose; peak heart rate at 2 ± 1 min, back to baseline 23 ± 19 min after the peak; one patient still above baseline at 60 min, without symptoms. Half-life: 30 min (Fares 2019); initial 2 to 4 min, intermediate about 30 min, terminal about 2 hours (FDA label, ASNC 2026; Bhave 2012 also about 2 hours). ASNC 2026, adult: BP every 2 min for at least 5 min; a re-dose after misadministration waits 150 min. | Wilkinson 2019 |
| Pediatric | Hypotension: 8 of 46 needed phenylephrine; sedation an independent risk. 46 examinations; sedation P = .040. 7 of the 8 had propofol. Treated with IV phenylephrine at the anesthesiologist’s discretion. An IV fluid bolus before regadenoson in sedated patients was tried in a very limited number of later examinations. Neither a phenylephrine dose nor a fluid volume is printed. | Wilkinson 2019 |
| Adult | Asystole and heart block within minutes, rarely; resuscitation equipment and trained staff at hand. FDA label sections 5.1, 5.2 and 5.4: fatal and nonfatal myocardial infarction, ventricular arrhythmias and cardiac arrest; third-degree heart block and asystole within minutes; have personnel and resuscitative equipment immediately available. ASNC 2026 p21: rare asystole, usually reverting to sinus rhythm by itself, may need aminophylline and/or atropine. | FDA label ASNC 2026 p21 |
| Adult | Seizure reported; ask about seizure history. With a history: aminophylline with caution, routine doses too (ASNC 2026 p51, FDA labels). | FDA label ASNC 2026 Aminophylline label |
| Reverse: aminophylline IV, slowly | ||
| Adult | Not for a seizure. Aminophylline, theophylline not recommended: may lower the seizure threshold. No pediatric document read addresses it. First line in adults is IV lorazepam (no pediatric dose). Its label: status epilepticus not established in pediatric patients; not for neonates; ventilatory support at hand. Lorazepam: Abidov 2018 and ASNC 2026 name it; the regadenoson and adenosine labels say emergent anticonvulsive management. Adult sources differ on the dose: about 2 mg IV for adults (ASNC 2026 p51); its label’s adult dose is 4 mg at 2 mg/min, 18 years and older. Lorazepam label: contraindicated with known sensitivity to benzodiazepines or its vehicle, acute narrow-angle glaucoma, sleep apnea syndrome, severe respiratory insufficiency unless mechanically ventilated, intra-arterial use, and in premature infants (benzyl alcohol); ventilatory support must be readily available. A trial against IV diazepam in 273 pediatric patients, 3 months to 17 years, failed to establish efficacy. Abidov 2018 calls the methylxanthine advice limited evidence and expert opinion. PALS 2025 has no lorazepam statement. | Abidov 2018 FDA label ASNC 2026 |
| Adult | Caffeine in a seizure, sources disagree: FDA labels and Abidov 2018 advise against every methylxanthine, caffeine included; ASNC 2026 prefers IV caffeine for reversal. ASNC 2026 pp 32 and 51 prefer it and give no citation for doing so. p32 prints an adult dose without naming the salt; Abidov 2018 Table 3 prints that dose as caffeine citrate. The dose is not shown here: no caffeine product label was read. Both FDA labels name caffeine as a methylxanthine. No pediatric dose in any document read. | FDA labels Abidov 2018 ASNC 2026 |
| Adult | Reverse for severe or symptomatic hypotension, sustained arrhythmia, symptomatic AV block, wheezing, poor perfusion, moderate to severe angina, or intolerable side effects. Full list. | ASNC 2026 Table 5, p32 |
| Pediatric | No weight-based rescue dose has been tested in any document read. | |
| Pediatric | Routine reversal, sources disagree: the pediatric series below gave it routinely; ASNC 2026 (nuclear) and Abidov 2018, adult, advise against. | Wilkinson 2019 Patel 2022 ASNC 2026 Abidov 2018 |
| Pediatric | 0.25 mg/kg under 40 kg, routine after stress imaging. Not tested as a rescue dose. Every patient, in Wilkinson 2019 and Noel 2018; hypotension in Wilkinson 2019 was treated with phenylephrine. All the pediatric data for 0.25 mg/kg and for 50 mg come from one center. At the limit, 0.25 mg/kg is 10 mg at 40 kg, then 50 mg above it. Our arithmetic: adult rescue of 50 to 125 mg at 70 kg is 0.7 to 1.8 mg/kg, well above 0.25 mg/kg. | Wilkinson 2019 Noel 2018 |
| Pediatric | 50 mg over 40 kg, routine: a 5-fold step from 0.25 mg/kg. | Noel 2017 Noel 2018 |
| Pediatric | 75 mg fixed, routine; median 61 kg. No minimum weight printed: 15 mg/kg at 5 kg. | Patel 2022 |
| Proposed | 50 mg fixed, no weight range given, rescue if side effects develop. At 5 kg this is 10 mg/kg, 40 times the 0.25 mg/kg above; 53 times at 3.8 kg, Wilkinson 2019’s smallest. Our arithmetic. Fares 2019 gives no weight limit and no citation for this dose. The pediatric cohorts read that used 50 mg gave it only above 40 kg, routinely (Noel 2017, Noel 2018). Aminophylline label (asthma and chronic lung disease, not stress testing): average child 1 to 9 y, loading dose 5.7 mg/kg over 30 min. 50 mg is 10 mg/kg at 5 kg, and 5 mg/kg, 20 times 0.25 mg/kg, at 10 kg. Extreme caution in seizure disorders; neonates and children under 1 y clear it slowly. No pediatric injection rate in any document read. Arithmetic: 0.25 mg/kg is 1.25 mg at 5 kg, 2.5 mg at 10 kg, 0.95 mg at 3.8 kg. Figure 1 of Fares 2019 draws aminophylline between stress and rest perfusion. In a shortage the authors allow theophylline or caffeine, without a dose; the seizure warning covers theophylline, and the sources disagree on caffeine. | Fares 2019 |
| Adult | Not for a seizure. Rescue aminophylline 50–125 mg over 30 s, may repeat, to 250 mg at most (ASNC 2026); 50–250 mg (FDA label). Pediatric rescue untested: weight warnings above. Arrhythmogenic: caution (SCMR 2020). 50 to 125 mg, may repeat, and routine reversal not recommended: Abidov 2018. 50 to 250 mg, 50 to 100 mg over 30 to 60 seconds: FDA label. Aminophylline’s own label: extreme caution in cardiac arrhythmias. ASNC 2026 pp 21 and 32 also say not routine, and p32 names theophylline and caffeine for a shortage; their doses are not shown here (labels not read). For stress CMR, Abidov 2018: a reversal agent can be given once first-pass stress perfusion images have been acquired, and a very serious adverse event should be reversed immediately; reversal may be needed in a minority (<25%) when rest perfusion is required. Routine use differs: Wilkinson 2019, Patel 2022 and Noel 2018 gave it to every patient; Noel 2017 says regardless of symptoms in its Methods and the majority of patients in its Discussion; SCMR 2020 says many sites do; AHA 2026 Table 2 pairs regadenoson with reversal; Bhave 2012 gave it to 10 of 20. | ASNC 2026 FDA label SCMR 2020 Abidov 2018 |
| Dose | ||
|---|---|---|
| Adult | 0.4 mg, about 10 s; 20–30 s may lessen hypotension. Sources differ. ASNC 2026 p20: about 10 s, and slower injections of 20 to 30 s may lead to less hypotension. FDA label: within 10 seconds, adhere to the recommended duration; in an animal study longer injection times may increase the duration and magnitude of the rise in coronary blood flow. | SCMR 2020 ASNC 2026 FDA label |
| Reverse: aminophylline IV, slowly | ||
| Adult | 100 mg routine at many sites, with caution: arrhythmogenic. 125 mg, study arm: reversal only partial at 15 min. 100 mg: SCMR 2020. 125 mg: Bhave 2012, 10 of 20 volunteers; residual hyperemia can lower perfusion reserve on rest images taken after stress. | SCMR 2020 Bhave 2012 |
Contraindications first: shared section
| Dose | ||
|---|---|---|
| Pediatric | No pediatric dose in any document read. The proposed protocol has none. Fares 2019 Table 3 lists cohorts that used it: Raimondi 2018 (132 patients after arterial switch), Vijarnsorn 2017 and Prakash 2004. Their doses have not been read. | Fares 2019 |
| Adult | 0.142 mg/kg/min (0.57 mg/kg total) over 4 min; 0.56 mg/kg in ASNC 2026. 60 mg at most. FDA label, for thallium imaging: a total beyond 60 mg is not needed. ASNC 2026 Table 10: 0.56 mg/kg, the 60 mg reached at 107 kg; it quotes the insert as not recommended. Vasu 2013, healthy adult volunteers, and Robbers-Visser 2009, a review without pediatric data: 0.56 mg/kg over 4 min. SCMR 2025 prints no dose, and the figure in SCMR 2020 has a unit error (see the method section), so neither is the source here; the label’s unit is mg. Contrast in the infusion’s last minute (SCMR 2020); imaging 4 min after it (Vasu 2013). Side effects: chest pain, headache, dizziness; rarely myocardial infarction, ventricular tachycardia, transient ischemic attack (SCMR 2020). Effects can persist up to 30 min (Robbers-Visser 2009, review). | FDA label ASNC 2026 Vasu 2013 |
| Give, watch, reverse | ||
| Review | Two IV lines. Half-life 30–45 min. Timing differs by source. Peak 7 to 15 min: Fares 2019 Table 2. FDA label: mean time to peak flow 6.5 min from the start of the infusion (2.5 to 8.7). SCMR 2020 gives contrast in the infusion’s last minute; Vasu 2013 imaged 4 min after it. | Fares 2019 |
| Adult | Not for a seizure (caffeine: sources disagree). Rescue, frequently needed: aminophylline 50–125 mg over 30 s, to 250 mg at most (ASNC 2026); 50–250 mg (FDA label). No pediatric dose. When to reverse, Adult. FDA label: for severe chest pain or bronchospasm, 50 to 100 mg over 30 to 60 seconds, in doses of 50 to 250 mg. Abidov 2018: 50 to 125 mg by slow injection; symptoms may last 15 to 25 min. Seizures: Abidov 2018 excludes them from the aminophylline indications for all three vasodilators and names lorazepam first; its methylxanthine sentence names adenosine and regadenoson. The dipyridamole label lists seizures and is silent on methylxanthines. ASNC 2026 pp 50 to 51 says no aminophylline for a seizure after any of the three and prefers IV caffeine for reversal, so the sources disagree on caffeine. | ASNC 2026 FDA label Abidov 2018 |
Contraindications first: shared section
| Dose, two IV lines | ||
|---|---|---|
| Proposed | Start 5–10 mcg/kg/min, up every 3 min, maximum 40. Step size is not stated and atropine is not mentioned. The pediatric paper it points to, Strigl 2009, started at 10; no pediatric cohort read started at 5 for ischemia testing; ASNC 2026, adult, starts at 5 or 10. Two IV lines: Fares 2019 Table 2, AHA 2026 Table 2. | Fares 2019 |
| Pediatric | 10, 20, 30, 40 mcg/kg/min; stages 3 or 3–5 min. Stages of 3 min: AHA 2026, Stagnaro 2023. 3 to 5 min: Strigl 2009. Single-center series. Strigl 2009: 32 studies in 28 patients, median 7.3 y (0.8 to 22 y), 63% under general anesthesia. Stagnaro 2023: 13 patients, 9 to 17 y, all awake. Beattie 2025: 80 studies in 64 patients, 0.5 to 22.4 y, 73% under general anesthesia, same center as Strigl 2009 and including its patients. AHA 2026 Table 2 gives this as the typical protocol, the same for stress echo and stress MRI. Strigl 2009 went to 50 mcg/kg/min in 3 of 32 studies, at the supervising physician’s choice. | AHA 2026 Strigl 2009 |
| Atropine contraindications | ||
| Pediatric | 0.01 mg/kg, Table 2: no increment or primary source. Label: usual initial 0.01–0.03 mg/kg, not well studied; coronary limit 0.03–0.04 mg/kg total. Label, section 8.4: pediatric recommendations are not based on clinical trials. Its coronary limit guards against tachycardia and myocardial oxygen demand. Its indication does not include stress testing. The adjacent line of the same AHA table carries the thousand-fold dobutamine misprint (see the method section), so read this entry with care. It sits in the stress echo row, carried to stress MRI by “Identical ... atropine considerations”. Fares 2019 does not mention atropine. Strigl 2009 and Beattie 2025 gave it if the heart rate response was inadequate and print no dose. Stagnaro 2023 gave it in selected cases to 6 patients aged 9 to 17 y: observed mean 0.287 ± 0.04 mg, not weight-based and not a protocol. A different setting: for premedication in emergency intubation, PALS 2025 says 0.02 mg/kg with no minimum dose may be considered (2b, C-LD). It gives no dose for stress testing. | AHA 2026 FDA label |
| Target heart rate | ||
| Proposed | 85% of maximal heart rate for age. | Fares 2019 |
| Pediatric | Series ran to 85% × (220 − age). Not established in children: reached in 6 of 32, and 10 of 13 awake and older. 6 of 32: Strigl 2009. 10 of 13: Stagnaro 2023. Still being studied: AHA 2026 Table 1. Strigl 2009 calls the formula’s applicability to children unsupported; Stagnaro 2023 says the target was defined only for adults. The heart rate or rate pressure product needed to reach the ischemic threshold is not established for the pediatric age (both). AHA 2026 Table 2 uses about 85% of maximal heart rate for age as the prompt for atropine and notes that general anesthesia may prevent reaching it. Observed, not thresholds: in Strigl 2009 heart rate ≥160 bpm in 27 of 32 and rate pressure product ≥20,000 in 27 of 31. Beattie 2025 also ran to the formula. | Strigl 2009 Stagnaro 2023 AHA 2026 |
| Watch, stop | ||
| Pediatric | Continuous ECG, oximetry; BP every 2 min. ST segments unreadable in the magnet. Strigl 2009: no serious adverse events, but too small to predict the incidence of complications; 3 of 32 stopped for chest pain or nausea, which subsided quickly on stopping. Stagnaro 2023: no major adverse events; 3 of 13 had mild symptoms. Doan 2021 abstract: 224 studies in 182 patients ≤20 y with AAOCA, no major events, minor events in 28 (12.5%). ASNC 2026, adult: serious events in 0.2% to 0.5%, the highest of the stress modalities. | Strigl 2009 |
| Pediatric | Stop criteria: none printed for children beyond the heart rate target. Adult: new wall motion abnormality, serious side effect or target heart rate (SCMR 2020); ASNC 2026 list. Strigl 2009 Table 2, 32 studies: maximum dose plus atropine without target 19; target 6; physician’s discretion near target 3; chest pain or nausea with refusal 3; inducible wall motion abnormality 1. Stagnaro 2023, 13 patients: target 10; maximum plus atropine 2; discretion near target with mild symptoms 1. AHA 2026 asks for clear criteria for intervention and cessation without stating them. ASNC 2026 Tables 5 and 6 are adult: When to stop or reverse, Adult. | Strigl 2009 SCMR 2020 |
| Pediatric | A negative study does not exclude anatomic obstruction. Read perfusion as well as wall motion. AHA 2026: perfusion abnormalities are more common than wall motion abnormalities in pediatric AAOCA. Doan 2021 abstract: inducible hypoperfusion in 31 of 221, with wall motion abnormality in 13 of those 31. Beattie 2025, positive meaning wall motion only: of 61 patients with a negative study, none had myocardial infarction, death or aborted sudden death over a median 7.4 y, but 4 had transplant or bypass surgery, all with significant obstruction at catheterization. | AHA 2026 Beattie 2025 |
| Reverse | ||
| Pediatric | Stop the infusion: half-life 2 min. Esmolol or IV metoprolol at hand: no pediatric dose in any document read. Half-life: Fares 2019 Table 2. Esmolol and sublingual nitroglycerin: Strigl 2009. IV metoprolol and sublingual nitroglycerin: Stagnaro 2023. No document prints a pediatric dose for any of them. ASNC 2026 p32 prints adult doses; they are not shown here. | Strigl 2009 Stagnaro 2023 |
| Dose | ||
|---|---|---|
| Not child-specific | Viability, contractile reserve: 5, 10, 20 mcg/kg/min. From the “Typical protocol” column of AHA 2026 Table 2, not its column on children; the text cites the ASE stress echo guideline for ischemic heart disease. In children and CHD: Fontan cohort, 92 patients, median 11.5 y, 7.5 mcg/kg/min; a smaller rise in ejection fraction went with more events (van den Bosch 2019, research letter). In Fontan patients at 7.5 mcg/kg/min, heart rate rose more than 150% from baseline in 10 of 37, and 5 mcg/kg/min was enough (Robbers-Visser 2009, review). | AHA 2026 |
| Adult | From 10, up 10 mcg/kg/min every 3 min, typically to 40. | SCMR 2020 |
| Adult | From 5 or 10, every 3 min, to 40; 50 mcg/kg/min for 3 more min in selected patients. | ASNC 2026 |
| Atropine | ||
| Adult | 0.25 mg fractions or 0.5 mg increments, both printed; maximum 2 mg. ASNC 2026: divided 0.25–0.5 mg, same maximum, after 40 mcg/kg/min or in some cases after 30. | SCMR 2020 ASNC 2026 |
| Target heart rate | ||
| Adult | 85% × (220 − age). | SCMR 2020 ASNC 2026 |
Sources: FDA labels for regadenoson, adenosine, dipyridamole, dobutamine, atropine, aminophylline, lorazepam; ASNC 2026; AHA 2026; SCMR 2020; SCMR CHD 2013; Fares 2019; Robbers-Visser 2009. Labels not read, doses not shown: theophylline, caffeine, esmolol, metoprolol, nitroglycerin, phenylephrine.
No list is complete; an empty list does not clear a patient.
| All agents | ||
|---|---|---|
| Adult | Caution: severe pulmonary hypertension; significant left main stenosis or high-risk coronary anatomy. | ASNC 2026 Table 4 |
| Adult | Heart transplant, sources disagree: exercise, regadenoson or dobutamine preferred; adenosine, more bradyarrhythmia and AV block. | ASNC 2026 p47 |
| Pediatric | Heart transplant: AHA 2026 Table 1, uncited: pediatric literature shows adenosine stress CMR safe despite conduction concerns. Regadenoson CMR (Husain 2021): no major events in 24, mean 16 y. AHA 2026 Table 1, allograft vasculopathy row, adenosine stress CMR: the majority of the literature is in adult transplant patients; no citation beside the pediatric sentence. Its text: single-center studies show regadenoson stress CMR feasible and safe in pediatric transplant patients, sensitivity and specificity not yet reported, citing Husain 2021. That paper, retrospective, one center: 26 recipients, mean 16.3 y, 62.4 kg, no anesthesia; regadenoson in 24, 6 to 10 mcg/kg to 400 mcg, then aminophylline 75 mg; no major adverse reactions, 1 minor. The patient with active rejection had no stress study; CAV grade 2 at most. It shares authors and the 75 mg with Patel 2022 and does not address adenosine safety. ASNC 2026 p47, adult: adenosine, AV block 44% vs 4% in a case series of 9, confirmed in 102; dipyridamole safety data limited within 2 to 3 years of transplant. | AHA 2026 Table 1 Husain 2021 |
| Adenosine, regadenoson, dipyridamole | ||
| Pediatric | Adenosine: second or third degree heart block; sinus node dysfunction; severe asthma or obstructive pulmonary disease; pregnancy. | SCMR CHD 2013 |
| Review | All three: SSS; high degree AV block; recent ACS; hypotension. Bronchospasm or asthma: relative (adenosine, dipyridamole), rare (regadenoson). SSS, sick sinus syndrome; ACS, acute coronary syndrome. Fares 2019 Table 2 lists contraindications and major adverse effects together, with adult studies and a review as its citations. AHA 2026: dobutamine for those who cannot tolerate vasodilators (eg, asthma). | Fares 2019 |
| Adult | Taking dipyridamole: no regadenoson or adenosine within 48 h. IV dipyridamole instead (no pediatric dose), oral continued; dobutamine second line. Robbers-Visser 2009 (review), adenosine: taking dipyridamole, active restrictive airway disease, 2nd or 3rd degree AV block. SCMR 2020 withholds dipyridamole 12 to 24 h before any vasodilator; ASNC 2026, at least 48 h; regadenoson label section 7.1, at least two days when possible. | ASNC 2026 Table 3 Robbers-Visser 2009 |
| Adult | Asthma, sources disagree: active disease with regular inhalers excludes all three (SCMR 2020); adenosine label, known or suspected; ASNC 2026, ongoing wheezing or a recent exacerbation, regadenoson preferred if stable. | SCMR 2020 FDA label ASNC 2026 |
| Adult | Seizure: adenosine, regadenoson: ask about seizure history; contraindicated with active seizures within 6 months (ASNC 2026 Table 3), a caution with dipyridamole; avoid if antiseizure medication is being titrated (pp 50-51). | FDA labels ASNC 2026 |
| Adult | Sinus node disease, sources disagree: regadenoson and adenosine labels contraindicate it without a functioning pacemaker; ASNC 2026 p44, generally acceptable; p28, a reason for dobutamine. | Regadenoson label Adenosine label ASNC 2026 |
| Dobutamine, atropine | ||
| Adult | FDA label: idiopathic hypertrophic subaortic stenosis; hypersensitivity. | FDA label |
| Review | Recent ACS; electrical or hemodynamic instability. | Fares 2019 |
| Review | CHD: obstructed systemic ventricular filling or ejection; 2nd or 3rd degree AV block; history of sustained ventricular tachycardia. | Robbers-Visser 2009 |
| Adult | Atropine, sources disagree: not with narrow-angle glaucoma, myasthenia gravis, obstructive uropathy or obstructive gastrointestinal disorders (SCMR 2020, ASNC 2026); its FDA label lists none, but warns of glaucoma, pyloric obstruction, urinary retention. | SCMR 2020 ASNC 2026 pp 30-31 FDA label |
Our note: numeric cut-offs here are adult; no document read gives pediatric ones. Mean resting systolic BP in Wilkinson 2019’s children was 90.4 mmHg, so neither ≤85 nor <90 mmHg reads across. The two adult documents differ on blood pressure: both are printed.
| ASNC 2026, nuclear imaging | ||
|---|---|---|
| Adult | All agents, contraindicated: systolic BP at rest ≥200 or diastolic ≥110 mmHg; symptomatic hypotension, or systolic BP at rest ≤85 mmHg without symptoms; third-degree AV block without a functioning pacemaker; acute coronary syndrome within 2 days or with ongoing symptoms; acutely rising troponin; acute decompensated heart failure; uncontrolled or unstable arrhythmia; symptomatic severe aortic stenosis; acute pulmonary embolism; acute aortic syndrome; acute significant illness; cannot cooperate or stay still. | ASNC 2026 Table 3 |
| Adult | All agents, caution: severe pulmonary hypertension; significant left main stenosis or high-risk coronary anatomy; large unrepaired aortic aneurysm; asymptomatic severe aortic stenosis; significant electrolyte abnormalities; active endocarditis; recent stroke, TIA or severe carotid stenosis; significant anemia or blood loss. Avoid with hemoglobin <7 g/dL, or potassium <3 or >5.5 mmol/L (expert consensus). | ASNC 2026 Table 4, pp 42, 46 |
| Adult | Adenosine, regadenoson, dipyridamole, contraindicated: second-degree Mobitz type 2 AV block or severe symptomatic bradycardia without a functioning pacemaker; symptomatic aortic aneurysm; caffeine within 12 h. Caution: heart rate ≤40 per min; junctional rhythm; acute left ventricular thrombus; caffeine within 24 h. | ASNC 2026 Tables 3, 4 |
| Adult | Regadenoson, adenosine, seizure risk: large hemorrhagic CVA within 3 months, avoid; remote or questionable seizure history, many clinicians would proceed. | ASNC 2026 pp 50-51 |
| Adult | Dobutamine, contraindicated: acute left ventricular thrombus; hypertrophic obstructive cardiomyopathy or other significant LVOT obstruction; prior VT; symptomatic or severely enlarged aortic aneurysm; poorly rate-controlled atrial fibrillation or flutter. Caution: frequent PVCs or NSVT; beta blockers above low doses. | ASNC 2026 Tables 3, 4 |
| SCMR 2020, FDA labels | ||
| Adult | Adenosine, regadenoson, dipyridamole: 2nd degree (type 2) or complete AV block; systolic BP <90 mmHg; hypertension >220/120 mmHg; sinus bradycardia <40 bpm; active bronchospastic disease, regular inhalers; hypersensitivity. | SCMR 2020 |
| Adult | Adenosine, regadenoson: second- or third-degree AV block or sinus node dysfunction, unless a pacemaker functions. Adenosine: known or suspected bronchospastic lung disease. Regadenoson: obtain a seizure history. Adenosine and regadenoson labels, section 4 and regadenoson section 5.8. The adenosine label also asks about seizure history. Dipyridamole label: hypersensitivity only. | FDA labels |
| Adult | Dobutamine: hypertension ≥220/120 mmHg; unstable angina; severe aortic stenosis (gradient >60 mmHg or area <1 cm²); complex arrhythmias; hypertrophic obstructive cardiomyopathy; myocarditis, endocarditis or pericarditis; uncontrolled heart failure. | SCMR 2020 |
| Adult | Aminophylline: not with hypersensitivity to theophylline or ethylenediamine. Extreme caution: seizure disorders, cardiac arrhythmias other than bradyarrhythmias, active peptic ulcer. | FDA label |
| Adult | Lorazepam: known sensitivity to benzodiazepines or its vehicle; acute narrow-angle glaucoma; sleep apnea syndrome; severe respiratory insufficiency unless mechanically ventilated; intra-arterial use; premature infants (benzyl alcohol). Ventilatory support must be readily available. | FDA label |
Stop or reverse, any agent:
Consider, any agent: persistent asymptomatic second-degree or complete AV block; other significant arrhythmia; ST depression >2 mm without suspected ischemia; severe or increasing chest pain of unclear cause. Vasodilators: less severe side effects or ischemic ECG changes. Dobutamine: systolic BP falling on consecutive readings, especially with ischemic ECG changes or angina: look for the cause, consider holding the rate or stopping.
ASNC 2026 Tables 5 and 6. ASNC 2026 revises the 2016 guideline (p2), which was not read. Abidov 2018’s list, based on it, differs: severe hypotension ≤80 mmHg; intolerable symptoms such as nausea, vomiting or abdominal pain. ASNC 2026 pp 31-32 still reverses for serious or intolerable side effects. Most effects are self-limiting and need no reversal (Abidov 2018). After regadenoson or dipyridamole, other rescue drugs go after aminophylline, not instead of it (ASNC 2026 pp 22, 25); Wilkinson 2019 treated hypotension with phenylephrine. No document read tests these in children. Our note: mean resting systolic BP in Wilkinson 2019’s children was 90.4 mmHg, so <80 and <90 mmHg do not read across, and ST segments cannot be read in the magnet (Strigl 2009).
Caffeine: the day of the examination (SCMR CHD 2013, adenosine); 24 h (Patel 2022); Adult at least 12 h, preferably 24 h, decaffeinated drinks too (ASNC 2026). No guideline read gives a pediatric interval in hours. Fares 2019 says it does not affect regadenoson (9 adults) or dobutamine (no citation); the sources above still hold it.
| Caffeine, before a vasodilator | ||
|---|---|---|
| Pediatric | The day of the examination, for adenosine (also aminophylline and nitrates) | SCMR CHD 2013 |
| Pediatric | 24 h, single-center study protocol, regadenoson | Patel 2022 |
| Adult | 12 h: testing contraindicated if used within it | AUC 2023 |
| Adult | 12–24 h (also theophylline and dipyridamole) | SCMR 2020 |
| Adult | At least 12 h, preferably 24 h, decaffeinated coffee, tea and soda too (also theophylline and caffeine-containing drugs, p20). Within 12 h a contraindication, within 24 h a caution. Advanced liver disease: ideally 1 week, or dobutamine | ASNC 2026 Tables 3, 4, p43 |
| Adult | A randomized trial found caffeine reduced regadenoson defects on nuclear imaging, as ASNC 2026 reports it; the trial itself was not read. Current methylxanthine medication: dobutamine instead. No document read addresses an infant on caffeine citrate | ASNC 2026 pp 28, 43 |
| Adult | Dipyridamole, at least 48 h, before regadenoson or adenosine | ASNC 2026 Table 3 |
| Adult | At least 12 h, regadenoson label, before imaging | FDA label |
| Adult | At least 12 h, study protocol | Karamitsos 2010 |
| Adult | At least 24 h, study protocol | Vasu 2013 |
| Review | 1 to 2 days (also theophylline) | Robbers-Visser 2009 |
| Review | Reduces sensitivity to adenosine and dipyridamole; no effect on regadenoson or dobutamine | Fares 2019 Table 2 |
| Adult | Coffee under 4 h before regadenoson: no effect on hyperemia by T1 mapping, in 9 adults. The source of the “no effect” entry in Fares 2019. | van Dijk 2017 |
| Before dobutamine | ||
| Pediatric | Beta-blockers and caffeine, at least 24 h | Strigl 2009 |
| Pediatric | Beta-blockers, 3 days | Stagnaro 2023 |
| Pediatric | Hold beta-blockers, avoid caffeine: no interval given | AHA 2026 Table 2 |
| Adult | Beta-blockers and nitrates, 12–24 h | SCMR 2020 |
| Adult | Beta-blockers, 4–5 half-lives unless unsafe. Caffeine and theophylline at least 12 h, preferably 24 h, and dipyridamole at least 48 h, in case a vasodilator is substituted | ASNC 2026 p29 |
| Median 36 y | Nitrates, beta-blockers, calcium antagonists, other negative inotropes and chronotropes, at least 48 h | Attanasio 2025 |
For stress CMR in children